1-methyl-4-[[(3R)-1-methylpyrrolidin-3-yl]methyl]piperazine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-methyl-4-[[(3R)-1-methylpyrrolidin-3-yl]methyl]piperazine
• 化学式: C₁₁H₂₃N₃
• 分子量: 197.32
• InChiKey: LLHUGXARJKYRNW-LLVKDONJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.7
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• [EN] NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF<br/>[FR] NOUVELLES URÉES AYANT UNE ACTIVITÉ DE DÉGRADATION DU RÉCEPTEUR DES ANDROGÈNES ET LEURS UTILISATIONS
  申请人：ACCUTAR BIOTECHNOLOGY INC

  公开号：WO2021061642A1

  公开（公告）日：2021-04-01

  The present disclosure relates to novel compounds, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and related diseases and conditions. In some embodiments, the compounds disclosed herein exhibit androgen receptor degradation activity.
• [EN] COMBINATIONS OF ESTROGEN RECEPTOR DEGRADERS AND CYCLIN-DEPENDENT KINASE INHIBITORS FOR TREATING CANCER<br/>[FR] ASSOCIATIONS D'AGENTS DE DÉGRADATION DU RÉCEPTEUR D'ŒSTROGÈNES ET D'INHIBITEURS DE KINASE DÉPENDANTE DE CYCLINES POUR LE TRAITEMENT DU CANCER
  申请人：ACCUTAR BIOTECHNOLOGY

  公开号：WO2021133886A1

  公开（公告）日：2021-07-01

  Provided herein are pharmaceutical combinations, compositions, and methods of using a compound with estrogen receptor (ER) degradation activity, such as a compound of formula (I) or a tautomer, stereoisomer or a mixture of stereoisomers, or a pharmaceutically acceptable salt, or hydrate thereof, wherein R1, Y, R22, R33, R2, p, X3, X4, and Z are defined herein and a cyclin-dependent kinase (CDK) inhibitor.